Loading stock…

Phathom Pharmaceuticals, Inc. (PHAT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Phathom Pharmaceuticals, Inc.

PHATMarket cap $0.54BPrice $6.8

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and sells vonoprazan-based drugs for acid reflux and stomach ulcers, treating a market where Big Pharma abandoned innovation decades ago. It's the first new class of acid-blocking medicine approved in the US since the 1980s.

In Bastion Portfolios?

52W Return-47%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+81%10

Rev CAGR (3y)+58%10

Rev CAGR (5y)+42%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+34177%10

EPS Growth Y+3+161%10

Quality

Margins

EBIT Margin-17%1

Net Income Margin-41%1

Free Cash Flow Margin-15%2

Debt

Net Debt/EBITDAna–

Efficiency

ROEna–

ROA-34%1

Earnings Stability22

GEAR+WEAK18

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)310

P/BVna–

EV Multiples

EV/EBITDA Fwd741

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-6.8%1

Dividend Yieldna–

Momentum

Short term

1 month return-28%1

3 month return-44%1

YTD return-59%1

Mid term

Price vs 52wHigh37%1

1 year return-38%1

Long term

3 year return-35%1

5 year return-79%1

Risk Shield

Price Risk

Beta2.01

Volatility66%2

Free Cash Flow

Free Cash Flow Margin-15%2

Free Cash Flow Yield-6.8%1

Quality

ROCE-25%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

PHATPhathom Pharmaceuticals

Revenue FY25$175M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+81%10

Revenue, next 3Y, CAGR+58%10

Revenue, next 5Y, CAGR+42%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+34177%10

EPS growth, FY28E+161%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue is set to grow 58%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 58%/yr from here.

The runway holds up: revenue is set to grow 42%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-28%1

3-month return-44%1

YTD return-59%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-38%1

3-year return-35%1

5-year return-79%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-35% over three years and -79% over five), behind 90% of the market.

It's down 38% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-28%), over three months (-44%) and so far this year (-59%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Phathom Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PHATPhathom Pharmaceuticals

Revenue FY25$175M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+81%10

Revenue, next 3Y, CAGR+58%10

Revenue, next 5Y, CAGR+42%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+34177%10

EPS growth, FY28E+161%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue is set to grow 58%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 58%/yr from here.

The runway holds up: revenue is set to grow 42%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-28%1

3-month return-44%1

YTD return-59%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-38%1

3-year return-35%1

5-year return-79%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-35% over three years and -79% over five), behind 90% of the market.

It's down 38% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-28%), over three months (-44%) and so far this year (-59%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Phathom Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community